AbCellera Biologics (NASDAQ:ABCL) and Intra-Cellular Therapies (NASDAQ:ITCI) Head to Head Analysis

AbCellera Biologics (NASDAQ:ABCL) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, dividends and risk.

Insider and Institutional Ownership

61.4% of AbCellera Biologics shares are owned by institutional investors. Comparatively, 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 28.0% of AbCellera Biologics shares are owned by company insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

AbCellera Biologics has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500.

Earnings & Valuation

This table compares AbCellera Biologics and Intra-Cellular Therapies”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AbCellera Biologics	$28.83 million	24.70	-$146.40 million	($0.55)	-4.35
Intra-Cellular Therapies	$680.50 million	20.50	-$139.67 million	($0.73)	-179.71

Intra-Cellular Therapies has higher revenue and earnings than AbCellera Biologics. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than AbCellera Biologics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares AbCellera Biologics and Intra-Cellular Therapies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AbCellera Biologics	-533.32%	-15.73%	-12.22%
Intra-Cellular Therapies	-14.07%	-9.93%	-8.38%

Analyst Ratings

This is a summary of current ratings and target prices for AbCellera Biologics and Intra-Cellular Therapies, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AbCellera Biologics	0	1	2	0	2.67
Intra-Cellular Therapies	0	9	5	1	2.47

AbCellera Biologics currently has a consensus price target of $7.00, indicating a potential upside of 192.89%. Intra-Cellular Therapies has a consensus price target of $106.08, indicating a potential downside of 19.14%. Given AbCellera Biologics’ stronger consensus rating and higher possible upside, research analysts plainly believe AbCellera Biologics is more favorable than Intra-Cellular Therapies.

Summary

Intra-Cellular Therapies beats AbCellera Biologics on 9 of the 15 factors compared between the two stocks.

About AbCellera Biologics

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company’s preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.